JB Chemicals & Pharmaceuticals Limited — PPTs, 04-02-2025: Investor Presentation

**Financial Highlights:**

JB Pharma reported revenue of INR 963 crores for Q3 FY25, representing a 14% year-on-year increase, and INR 2,969 crores for the first nine months, up 13%. The domestic formulations segment surged 22% to INR 566 crores, cementing JB Pharma's reputation as a fast-growing entity in the sector. The operating EBITDA rose by 15% to INR 270 crores, with margins improving to 28.1%. Net profit also saw a notable 22% increase year-on-year, reaching INR 162 crores.

**Strategic Initiatives and Growth Drivers:**

The company continues to focus on its India branded formulations, CDMO, and select international markets, which have proven resilient even amid global volatility. New projects in the CDMO sector are expected to contribute positively to growth.

**Business Developments:**

The CDMO business excelled with a growth of 33%, and the company is enhancing its pipeline for international product commercialization. This positions JB Pharma favorably for continued expansion.

**Market Position and Competitive Advantage:**

JB Pharma has consistently outperformed the Indian pharmaceuticals market, particularly in chronic therapy segments, marking it as a competitive leader with significant market share gains.

**Investor Implications:**

The observed growth trajectory suggests a strong potential for future returns, bolstered by strategic acquisitions and operational efficiencies. Investors should maintain a positive outlook given the solid performance and clear growth strategies in place.